Loading...
•
Sep 30, 2021
NextCure Q3 2021 Earnings Report
NextCure reported financial results for the third quarter of 2021 and provided a business update.
Key Takeaways
NextCure reported its third quarter 2021 financial results and provided a business update, highlighting upcoming presentations of clinical and biomarker data for its NC318 and NC410 programs at the SITC annual meeting.
Presented clinical and biomarker data for NC318 and NC410 programs at the SITC annual meeting.
Hosted a virtual research and development update event following the SITC conference on November 15th.
Dr. Roy Herbst highlighted the significant remaining unmet need in the treatment of lung cancer at the R&D update event.
Dr. Herbst is a collaborator in the Phase 2 investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with advanced non-small cell lung cancer.
NextCure
NextCure
Forward Guidance
NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditure requirements into the second half of 2023.